The Alliance for Regenerative Medicine (ARM) and MEP Dr. Stelios Kympouropoulos held an event on November 29 at the European Parliament to highlight concerning trends for advanced therapy medicinal product (ATMP) developers, clinical trials, and investment in the European Union (EU).
At the event, ARM and many speakers emphasized the EU can reverse its declining competitiveness and ensure patient access to transformative treatments if it modernizes its policy and regulatory framework to reflect the distinct promise of cell and gene therapies as the future of medicine.
To learn more read ARM’s call to action or watch the event recording.
Dr. Stelios Kympouropoulos, MEP, European People’s Party
Tim Hunt, Chief Executive Officer, Alliance for Regenerative Medicine
Emily Whitehead & Tom Whitehead, Emily Whitehead Foundation
Sylvain Giraud, Head of Unit ‘Medical Products: Quality, Safety, Innovation’, DG Sante, European Commission
Patrick Celis, Scientific Administrator, Committee for Advanced Therapies, European Medicines Agency
Lucy Ellerker, Patient Advocate
Simone Boselli, Director of Public Affairs, EURORDIS Rare Disease Europe
Susana Solís Perez, MEP
Chris Vann, Chief Operating Officer at Autolus, and Member of the Alliance for Regenerative Medicine’s Board
Dr Miguel Forte, President-Elect of the International Society for Cell & Gene Therapy, and Member of the Alliance for Regenerative Medicine’s Board
Watch the event recording
Read ARM’s Call to Action for Policymakers
